Its diabetes portfolio features innovative treatments such as SGLT2 inhibitors (e.g., FORXIGA), GLP-1 receptor agonists (e.g., Bydureon BCise), and DPP-4 inhibitors (e.g., Saxagliptin), aimed at ...

AstraZeneca announced that the EC green-lighted the new formulation of the once-weekly type-2 diabetes injection, which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension).

and AstraZeneca’s Bydureon (exenatide). According to the FDA, the incidence of type 2 diabetes in children increased by 4.8% per year from 2002 to 2015, with an estimated 28,000 cases in 2017 ...